- SEK2.01bn
- SEK1.43bn
Brief: InDex Pharmaceuticals Q1 Operating Loss Narrows To SEK 9.3 Mln
Brief: Index Pharmaceuticals Gets Patent For Additional DIMS Compounds Granted In Europe
Brief: Index Pharmaceuticals Enters Agreement With Parexel Biotech
Brief: Index Pharmaceuticals Holding AB - Q4 Result After Tax Amounted To Sek -10.1 Million
Brief: InDex Pharmaceuticals' Rights Issue Is Oversubscribed
Brief: InDex Pharmaceuticals Carries Out Fully Guaranteed Rights Issue Of Around SEK 533 Mln
Brief: Index Pharmaceuticals Q3 Operating Loss Narrows To SEK 7.7 Mln
Brief: InDex Pharmaceuticals To Carry Out Rights Issue Of About SEK 500 Mln
Brief: Index Pharmaceuticals Q2 Operating Loss At SEK 15.6 Mln
Brief: Index Pharmaceuticals To Present Successful Results Of Conduct Study
Brief: Index Pharmaceuticals Q1 Operating Loss Widens To SEK 24.0 Mln
Brief: Index Pharmaceuticals Advances Cobitolimod Further Towards Phase III
Brief: Index Pharmaceuticals Gets Grant From Vinnova
Brief: Index Pharmaceuticals Q4 Operating Loss Widens To SEK 25.6 Mln
Brief: Index Pharmaceuticals' Analysis Of CONDUCT Study Confirms Successful Top Line Results, Supports Strategy Going Forward
Brief: Index Pharmaceuticals Q3 Operating Loss Widens To SEK 27.2 Mln
Brief: InDex Pharmaceuticals Holding Raises SEK 140 Mln In Directed Share Issue
Brief: Index Pharmaceuticals Meets Primary Endpoint In Phase IIb Study CONDUCT With Cobitolimod In Ulcerative Colitis
Brief: Index Pharmaceuticals Q2 Operating Loss Narrows To SEK 17.7 Million